How do regional sickness funds encourage more rational use of medicines, including the increase of generic uptake? A case study from Austria
Journal Title: Generics and Biosimilars Initiative Journal - Year 2013, Vol 2, Issue 2
Abstract
Objective: To analyse similarities and differences between activities carried out by Austrian sickness funds to encourage more rational use of medicines, including increasing generics uptake. Methods: Semi-structured interviews with pharmacoeconomic unit staff of four regional sickness funds in Austria. Results: Sickness funds include a variety of activities. The main target group is prescribers, who are provided information and educational materials, and whose prescription patterns are monitored. All surveyed sickness funds encourage doctors to prescribe more generics as part of an overall strategy to improved rational prescribing. Sickness funds provide patient information; however, pharmacists are not considered to be a target group. In recent years, sickness funds responsible for primary care have launched joint initiatives with hospitals, e.g. training of hospital staff, with the aim of improving pharmacotherapy at the interface between outpatient (ambulatory) and hospital care. Discussion: All surveyed sickness funds carry out similar activities; however, the design of the individual measures differs between them as they have been adapted to meet regional differences. Conclusion: Sickness funds have initiated a number of regional activities. The effect of these activities could be reinforced if national policies were in place to support them. Examples include generics substitution and International Nonproprietary Name prescribing, regular analysis and publication of pharmaceutical spending and consumption, and improvement of pharmacotherapy at the interface between outpatient and hospital care.
Authors and Affiliations
Sabine Vogler, Nina Zimmermann
Keywords
Related Articles
- EP ID EP354987
- DOI 10.5639/gabij.2013.0202.027
- Views 86
- Downloads 0
New CHMP guideline on immunogenicity of monoclonal antibodies
The importance of monoclonal antibodies as a product class and the challenge of assessing unwanted immunogenicity for these products have prompted the drafting of a new CHMP (Committee for Medicinal Products for Human Us...
Reference pricing systems in Europe: characteristics and consequences
Introduction: A reference pricing system is a system that establishes a common reimbursement level or reference price for a group of interchangeable medicines, i.e. the reference group. This article provides an overview...
Critical immunogenicity differences will be obscured by a common INN for biosimilars
Information about variable immunogenicity arising from formulation differences between competing biosimilars is critical for informed judgments by prescribing physicians. Use of a common INN for biosimilars will obfuscat...
New product-specific bioequivalence guidance
For harmonization of the authorization requirements for specific generic applications within the EU, consistent criteria were drafted for 16 active substances, which are out now for public consultation.
Establishment of reference standards in biosimilar studies
When an innovative biological product goes off-patent, biopharmaceutical or biotechnological companies may file an application for regulatory approval of biosimilar products. In practice, however, important information o...